330 related articles for article (PubMed ID: 22202493)
1. Exogenous glucagon-like peptide-1 for hyperglycemia in critically ill patients.
Pinelli NR; Jones MC; Monday LM; Smith Z; Rhoney DH
Ann Pharmacother; 2012 Jan; 46(1):124-9. PubMed ID: 22202493
[TBL] [Abstract][Full Text] [Related]
2. Intensive insulin therapy for critically ill patients.
Lewis KS; Kane-Gill SL; Bobek MB; Dasta JF
Ann Pharmacother; 2004; 38(7-8):1243-51. PubMed ID: 15187219
[TBL] [Abstract][Full Text] [Related]
3. Glucose control in the intensive care unit.
Fahy BG; Sheehy AM; Coursin DB
Crit Care Med; 2009 May; 37(5):1769-76. PubMed ID: 19325461
[TBL] [Abstract][Full Text] [Related]
4. Hyperglycemia management using insulin in the acute care setting: therapies and strategies for care in the non-critically ill patient.
Kirk JK; Oldham EC
Ann Pharmacother; 2010; 44(7-8):1222-30. PubMed ID: 20571106
[TBL] [Abstract][Full Text] [Related]
5. Addressing hyperglycemia from hospital admission to discharge.
Moghissi ES
Curr Med Res Opin; 2010 Mar; 26(3):589-98. PubMed ID: 20078323
[TBL] [Abstract][Full Text] [Related]
6. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting.
Sokos GG; Bolukoglu H; German J; Hentosz T; Magovern GJ; Maher TD; Dean DA; Bailey SH; Marrone G; Benckart DH; Elahi D; Shannon RP
Am J Cardiol; 2007 Sep; 100(5):824-9. PubMed ID: 17719327
[TBL] [Abstract][Full Text] [Related]
7. The glucoregulatory benefits of glucagon-like peptide-1 (7-36) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study.
Galiatsatos P; Gibson BR; Rabiee A; Carlson O; Egan JM; Shannon RP; Andersen DK; Elahi D
Crit Care Med; 2014 Mar; 42(3):638-45. PubMed ID: 24247476
[TBL] [Abstract][Full Text] [Related]
8. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
[TBL] [Abstract][Full Text] [Related]
9. Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials.
Pittas AG; Siegel RD; Lau J
Arch Intern Med; 2004 Oct; 164(18):2005-11. PubMed ID: 15477435
[TBL] [Abstract][Full Text] [Related]
10. [Glycaemia control in critically ill patients is justified and effective].
Rybka J
Vnitr Lek; 2010 Sep; 56(9 Suppl):977-87. PubMed ID: 21137171
[TBL] [Abstract][Full Text] [Related]
11. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study.
Deane AM; Chapman MJ; Fraser RJ; Burgstad CM; Besanko LK; Horowitz M
Crit Care; 2009; 13(3):R67. PubMed ID: 19439067
[TBL] [Abstract][Full Text] [Related]
12. Intravenous GLP-1 (7-36) amide for prevention of hyperglycemia during cardiac surgery: a randomized, double-blind, placebo-controlled study.
Kohl BA; Hammond MS; Cucchiara AJ; Ochroch EA
J Cardiothorac Vasc Anesth; 2014 Jun; 28(3):618-25. PubMed ID: 24144627
[TBL] [Abstract][Full Text] [Related]
13. Hyperglycemia in the hospital setting: the case for improved control among non-diabetics.
Conner TM; Flesner-Gurley KR; Barner JC
Ann Pharmacother; 2005 Mar; 39(3):492-501. PubMed ID: 15701779
[TBL] [Abstract][Full Text] [Related]
14. Drug-drug interactions with glucagon-like peptide-1 receptor agonists.
Hurren KM; Pinelli NR
Ann Pharmacother; 2012 May; 46(5):710-7. PubMed ID: 22510669
[TBL] [Abstract][Full Text] [Related]
15. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia.
Deane AM; Chapman MJ; Fraser RJ; Summers MJ; Zaknic AV; Storey JP; Jones KL; Rayner CK; Horowitz M
Crit Care Med; 2010 May; 38(5):1261-9. PubMed ID: 20228679
[TBL] [Abstract][Full Text] [Related]
16. Understanding glycemic control in the critically ill: 2011 update.
Krinsley JS
Hosp Pract (1995); 2011 Apr; 39(2):47-55. PubMed ID: 21576897
[TBL] [Abstract][Full Text] [Related]
17. Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes.
Deane AM; Summers MJ; Zaknic AV; Chapman MJ; Fraser RJ; Di Bartolomeo AE; Wishart JM; Horowitz M
Crit Care; 2011; 15(1):R35. PubMed ID: 21255422
[TBL] [Abstract][Full Text] [Related]
18. [Insulin infusion for critically ill patients].
Skeie S; Søreide E; Cooper J
Tidsskr Nor Laegeforen; 2007 Sep; 127(18):2378-81. PubMed ID: 17895943
[TBL] [Abstract][Full Text] [Related]
19. Next-generation GLP-1 therapy: an introduction to liraglutide.
Repas T
Postgrad Med; 2011 Sep; 123(5):239-47. PubMed ID: 21904107
[TBL] [Abstract][Full Text] [Related]
20. The potential role of glucagon-like peptide-1 or its analogues in enhancing glycaemic control in critically ill adult patients.
Combes J; Borot S; Mougel F; Penfornis A
Diabetes Obes Metab; 2011 Feb; 13(2):118-29. PubMed ID: 21199263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
